Upcoming UNICEF Tender: December 2024

In a continued effort to support global health initiatives, UNICEF is set to release a new tender for essential insulin products in December 2024. This tender aims to ensure the availability of critical insulin medications to support children and families affected by diabetes around the world by UNICEF Tender. Here’s a detailed look at the products included in the upcoming tender:

1. Short-acting Human Insulin (Soluble) Injection
Short-acting human insulin is vital for managing blood glucose levels, especially around meal times. It begins to work within 30 minutes and its effects last for several hours. This type of insulin is essential for managing diabetes in both emergency settings and daily care.

2. Intermediate-acting Human Insulin Injection
Intermediate-acting insulin plays a role in maintaining baseline insulin levels. It typically starts to work within 1 to 2 hours and has a peak activity period of 4 to 12 hours, making it a fundamental component for diabetes management in many patients.

3. Biphasic Human Insulin (30% Short-acting Insulin + 70% Intermediate-acting Insulin)
Combining 30% short-acting and 70% intermediate-acting insulin, this biphasic formulation offers a convenient option for patients requiring both rapid onset and sustained insulin action. This combination simplifies the regimen, potentially improving adherence to treatment protocols.

4. Long-acting Insulin Analogues
Long-acting insulin analogues are designed to provide a steady insulin release over an extended period, often lasting up to 24 hours. This type of insulin mimics the body’s natural, basal insulin release, helping to maintain consistent blood glucose levels with fewer injections.

UNICEF’s upcoming tender underscores its commitment to improving health outcomes for those affected by diabetes, particularly in low-resource settings. By ensuring the availability of these essential insulin products, UNICEF aims to support better health management and improve the quality of life for millions.

Stay tuned for more updates as the tender release approaches. This initiative marks a significant step towards addressing the global diabetes challenge and ensuring that lifesaving medications reach those who need them most.

Note:

• FindmyCustomer offers strategic partnership support for Pharma business through its company “Amedra Healthcare.” For business inquiries, please contact us at director@amedra.in
• To receive notification of such exclusive high value pharma leads at no cost, share this lead on your social media and tag us.